



By EVERNORTH

1199 SEIU Benefit Funds
Medical Oncology Code List

*****Please note: This list is constantly evolving as new drugs come to market and are approved by the FDA as well as with any HCPC code changes issued by CMS. Please contact 1199 SEIU Benefit Funds or eviCore, if the drug you are requesting is not contained on this list, to determine if prior authorization is needed*****

Effective Date: 01/01/24

Description	Alt Descriptions	HCPCS Code	Program	Administration Technique	Drug Class	Dual Indication symbol - 1199	1199 SEIU National Benefit Fund	Drug Comments
5-Fluorouracil - Topical	5FU Cream, Efudex, Carac, Fluoroplex	J3490	Medical Oncology - CHEMO	TOPICAL	Primary		Y	
5-Fluorouracil- Injection	5FU, Adrucil	J9190	Medical Oncology - CHEMO	INJECTABLE	Primary		Y	
Abemaciclib - oral	Verzenio	J8999	Medical Oncology - CHEMO	ORAL	Primary		Y	
Abiraterone Acetate - oral	Yonsa (not interchangeable with Zytiga)	J8999	Medical Oncology - CHEMO	ORAL	Primary		Y	
Abiraterone Acetate - oral	Zytiga (not interchangeable with Yonsa)	J8999	Medical Oncology - CHEMO	ORAL	Primary		Y	
Acalabrutinib - oral	Calquence	J8999	Medical Oncology - CHEMO	ORAL	Primary		Y	
Acitretin - oral	Soriatane	J8499	Medical Oncology - CHEMO	ORAL	Primary		Y	
Adagrasib - oral	Krazati	J8999	Medical Oncology - CHEMO	ORAL	Primary		Y	
Ado-Trastuzumab Emtansine	Kadcyla	J9354	Medical Oncology - CHEMO	INJECTABLE	Primary		Y	
Afatinib - oral	Gilotrif	J8999	Medical Oncology - CHEMO	ORAL	Primary		Y	
Aldesleukin	Proleukin, Interleukin-2	J9015	Medical Oncology - CHEMO	INJECTABLE	Primary		Y	
Alectinib - oral	Alecensa	J8999	Medical Oncology - CHEMO	ORAL	Primary		Y	
All-trans Retinoic Acid - oral	Vesanoid, ATRA, Tretinoin	J8999	Medical Oncology - CHEMO	ORAL	Primary		Y	
Alpelisib - oral	Piqray	J8999	Medical Oncology - CHEMO	ORAL	Primary		Y	
Amivantamab-vmjw	Rybrevant	J9061	Medical Oncology - CHEMO	INJECTABLE	Primary		Y	
Apalutamide - oral	Erleada	J8999	Medical Oncology - CHEMO	ORAL	Primary		Y	
Aprepitant	Cinvanti	J0185	Medical Oncology - SPORT	INJECTABLE	Supportive - Antiemetic		Y	
Aprepitant - oral	Emend	J8501	Medical Oncology - SPORT	ORAL	Supportive - Antiemetic		Y	
Arsenic Trioxide	Trisenox	J9017	Medical Oncology - CHEMO	INJECTABLE	Primary		Y	
Asciminib - oral	Scemblix	J8999	Medical Oncology - CHEMO	ORAL	Primary		Y	
Asparaginase	Erwinaze	J9019	Medical Oncology - CHEMO	INJECTABLE	Primary		Y	

Effective Date: 01/01/24

Description	Alt Descriptions	HCPCS Code	Program	Administration Technique	Drug Class	Dual Indication symbol - 1199	1199 SEIU National Benefit Fund	Drug Comments
Asparaginase erwinia chrysanthemi (recombinant)-rywn	Rylaze	J9021	Medical Oncology - CHEMO	INJECTABLE	Primary		Y	
Atezolizumab	Tecentiq	J9022	Medical Oncology - CHEMO	INJECTABLE	Primary		Y	
Avapritinib - oral	Ayvakit	J8999	Medical Oncology - CHEMO	ORAL	Primary		Y	
Avelumab	Bavencio	J9023	Medical Oncology - CHEMO	INJECTABLE	Primary		Y	
Axitinib - oral	Inlyta	J8999	Medical Oncology - CHEMO	ORAL	Primary		Y	
Azacitidine	Vidaza	J9025	Medical Oncology - CHEMO	INJECTABLE	Primary		Y	
Azacitidine - oral	Onureg	J8999	Medical Oncology - CHEMO	ORAL	Primary		Y	
BCG	TheraCys, Tice	J9030	Medical Oncology - CHEMO	INJECTABLE	Primary		Y	
Belantamab Mafodotin-blmf	Blenrep	J9037	Medical Oncology - CHEMO	INJECTABLE	Primary		Y	
Belinostat	Beleodaq	J9032	Medical Oncology - CHEMO	INJECTABLE	Primary		Y	
Belzutifan - oral	Welireg	J8999	Medical Oncology - CHEMO	ORAL	Primary		Y	
Bendamustine HCL	Belrapzo	J9036	Medical Oncology - CHEMO	INJECTABLE	Primary		Y	
Bendamustine HCL	Bendeka	J9034	Medical Oncology - CHEMO	INJECTABLE	Primary		Y	
Bendamustine HCL	Treanda	J9033	Medical Oncology - CHEMO	INJECTABLE	Primary		Y	
Bendamustine HCL (Apotex)		J9058	Medical Oncology - CHEMO	INJECTABLE	Primary		Y	
Bendamustine HCL (Baxter)		J9059	Medical Oncology - CHEMO	INJECTABLE	Primary		Y	
Bendamustine HCL (Vivimusta)		J9056	Medical Oncology - CHEMO	INJECTABLE	Primary		Y	
Bevacizumab	Avastin	J9035	Medical Oncology - CHEMO	INJECTABLE	Primary	◆	Y	
Bevacizumab (Radiation Necrosis)	Avastin	J9035	Medical Oncology - SPORT	INJECTABLE	Supportive	◆	Y	Supportive pathway for the use of Avastin to treat Radiation Induced Necrosis of the CNS
Bevacizumab-adcd	Vegzelma	Q5129	Medical Oncology - SPORT	INJECTABLE	Supportive		Y	Supportive pathway for the use of Vegzelma to treat Radiation Induced Necrosis of the CNS
Bevacizumab-adcd	Vegzelma	Q5129	Medical Oncology - CHEMO	INJECTABLE	Primary		Y	
Bevacizumab-awwb	Mvasi	Q5107	Medical Oncology - CHEMO	INJECTABLE	Primary - Biosimilar	◆	Y	
Bevacizumab-awwb (Radiation Necrosis)	Mvasi	Q5107	Medical Oncology - SPORT	INJECTABLE	Supportive	◆	Y	Supportive pathway for the use of Mvasi to treat Radiation Induced Necrosis of the CNS
Bevacizumab-bvzr	Zirabev	Q5118	Medical Oncology - SPORT	INJECTABLE	Supportive	◆	Y	Supportive pathway for the use of Zirabev to treat Radiation Induced Necrosis of the CNS
Bevacizumab-bvzr	Zirabev	Q5118	Medical Oncology - CHEMO	INJECTABLE	Primary - Biosimilar	◆	Y	
Bevacizumab-maly	Almysys	Q5126	Medical Oncology - CHEMO	INJECTABLE	Primary - Biosimilar	◆	Y	
Bevacizumab-maly (Radiation Necrosis)	Almysys	Q5126	Medical Oncology - SPORT	INJECTABLE	Supportive	◆	Y	Supportive pathway for the use of Almysys to treat Radiation Induced Necrosis of the CNS

Effective Date: 01/01/24

Description	Alt Descriptions	HCPCS Code	Program	Administration Technique	Drug Class	Dual Indication symbol - 1199	1199 SEIU National Benefit Fund	Drug Comments
Bexarotene - oral	Targretin	J8999	Medical Oncology - CHEMO	ORAL	Primary		Y	
Bexarotene - topical	Targretin gel	C9399	Medical Oncology - CHEMO	TOPICAL	Primary		Y	
Bexarotene - topical	Targretin gel	J3490	Medical Oncology - CHEMO	TOPICAL	Primary		Y	
Binimetinib - oral	Mektovi	J8999	Medical Oncology - CHEMO	ORAL	Primary		Y	
Bleomycin	Blenoxane	J9040	Medical Oncology - CHEMO	INJECTABLE	Primary		Y	
Blinatumomab	Blincyto	J9039	Medical Oncology - CHEMO	INJECTABLE	Primary		Y	
Bortezomib	Velcade	J9041	Medical Oncology - CHEMO	INJECTABLE	Primary		Y	
Bortezomib (Dr. Reddy's)		J9046	Medical Oncology - CHEMO	INJECTABLE	Primary		Y	
Bortezomib (Fresenius Kabi)		J9048	Medical Oncology - CHEMO	INJECTABLE	Primary		Y	
Bortezomib (Hospira)		J9049	Medical Oncology - CHEMO	INJECTABLE	Primary		Y	
Bortezomib (maia)		J9051	Medical Oncology - CHEMO	INJECTABLE	Primary		Y	
Bosutinib - oral	Bosulif	J8999	Medical Oncology - CHEMO	ORAL	Primary		Y	
Brentuximab Vedotin	Adcetris	J9042	Medical Oncology - CHEMO	INJECTABLE	Primary		Y	
Brigatinib - oral	Alunbrig	J8999	Medical Oncology - CHEMO	ORAL	Primary		Y	
Burosumab-twza	Crysvita	J0584	Medical Oncology - SPORT	INJECTABLE	Supportive	◆	Y	
Cabazitaxel	Jevtana	J9043	Medical Oncology - CHEMO	INJECTABLE	Primary		Y	
Cabazitaxel (sandoz)		J9064	Medical Oncology - CHEMO	INJECTABLE	Primary		Y	
Cabozantinib - oral	Cabometyx	J8999	Medical Oncology - CHEMO	ORAL	Primary		Y	
Cabozantinib - oral	Cometriq	J8999	Medical Oncology - CHEMO	ORAL	Primary		Y	
Calaspargase pegol-mknl	Asparlas	J9118	Medical Oncology - CHEMO	INJECTABLE	Primary		Y	
Capecitabine - oral	Xeloda (150 mg)	J8520	Medical Oncology - CHEMO	ORAL	Primary		Y	
Capecitabine - oral	Xeloda (500 mg)	J8521	Medical Oncology - CHEMO	ORAL	Primary		Y	
Capivasertib - oral	Truqap	J8999	Medical Oncology - CHEMO	ORAL	Primary		Y	New primary oral chemotherapy effective: 12/06/23
Capmatinib - oral	Tabrecta	J8999	Medical Oncology - CHEMO	ORAL	Primary		Y	
Carboplatin	Paraplatin	J9045	Medical Oncology - CHEMO	INJECTABLE	Primary		Y	
Carfilzomib	Kyprolis	J9047	Medical Oncology - CHEMO	INJECTABLE	Primary		Y	
Carmustine	BiCNU, BCNU	J9050	Medical Oncology - CHEMO	INJECTABLE	Primary		Y	
Carmustine (accord)		J9052	Medical Oncology - CHEMO	INJECTABLE	Primary		Y	New manufacture HCPC Code: J9052 for carmustine, effective: 01/01/24
Cemiplimab-rwc	Libtayo	J9119	Medical Oncology - CHEMO	INJECTABLE	Primary		Y	
Ceritinib - oral	Zykadia	J8999	Medical Oncology - CHEMO	ORAL	Primary		Y	

Effective Date: 01/01/24

Description	Alt Descriptions	HCPCS Code	Program	Administration Technique	Drug Class	Dual Indication symbol - 1199	1199 SEIU National Benefit Fund	Drug Comments
Cetuximab	Erbixux	J9055	Medical Oncology - CHEMO	INJECTABLE	Primary		Y	
Chlorambucil - oral	Leukeran	J8999	Medical Oncology - CHEMO	ORAL	Primary	◆	Y	
Chlorambucil - oral	Leukeran	S0172	Medical Oncology - CHEMO	ORAL	Primary	◆	Y	
Cisplatin	Platinol	J9060	Medical Oncology - CHEMO	INJECTABLE	Primary		Y	
Cladribine	Leustatin	J9065	Medical Oncology - CHEMO	INJECTABLE	Primary		Y	
Clofarabine	Clolar	J9027	Medical Oncology - CHEMO	INJECTABLE	Primary		Y	
Cobimetinib - oral	Cotellic	J8999	Medical Oncology - CHEMO	ORAL	Primary		Y	
Crizotinib - oral	Xalkori	J8999	Medical Oncology - CHEMO	ORAL	Primary		Y	
Cyclophosphamide - inj	Cytosan, Endoxan-Asta	J9070	Medical Oncology - CHEMO	INJECTABLE	Primary		Y	
Cyclophosphamide - inj (auromedic)	Cyclophosphamide - inj (auromedics) 10 mg	J9071	Medical Oncology - CHEMO	INJECTABLE	Primary		Y	
Cyclophosphamide - inj (dr. reddy's)		J9072	Medical Oncology - CHEMO	INJECTABLE	Primary		Y	New manufacture code: J9072 for cyclophosphamide inj, effective: 01/01/24
Cytarabine	Ara-C	J9100	Medical Oncology - CHEMO	INJECTABLE	Primary		Y	
Cytarabine-Liposome	DepoCyt	J9098	Medical Oncology - CHEMO	INJECTABLE	Primary		Y	
Dabrafenib - oral	Tafinlar	J8999	Medical Oncology - CHEMO	ORAL	Primary		Y	
Dabrafenib - oral tablet	Tafinlar	J8999	Medical Oncology - CHEMO	ORAL	Primary		Y	
Dacarbazine	DTIC-Dome	J9130	Medical Oncology - CHEMO	INJECTABLE	Primary		Y	
Dacomitinib - oral	Vizimpro	J8999	Medical Oncology - CHEMO	ORAL	Primary		Y	
Dactinomycin	Cosmegen, Actinomycin	J9120	Medical Oncology - CHEMO	INJECTABLE	Primary		Y	
Daratumumab	Darzalex	J9145	Medical Oncology - CHEMO	INJECTABLE	Primary		Y	
Daratumumab and hyaluronidase-fihj	Darzalex Faspro	J9144	Medical Oncology - CHEMO	INJECTABLE	Primary		Y	
Darbepoetin alfa	Aranesp	J0881	Medical Oncology - SPORT	INJECTABLE	Supportive	◆	Y	
Darolutamide - oral	Nubeqa	J8999	Medical Oncology - CHEMO	ORAL	Primary		Y	
Dasatinib - oral	Sprycel	J8999	Medical Oncology - CHEMO	ORAL	Primary		Y	
Daunorubicin	Cerubidine	J9150	Medical Oncology - CHEMO	INJECTABLE	Primary		Y	
Decitabine	Dacogen	J0894	Medical Oncology - CHEMO	INJECTABLE	Primary		Y	
Decitabine (sun pharma)		J0893	Medical Oncology - CHEMO	INJECTABLE	Primary		Y	
Decitabine and cedazuridine - oral	Inqovi	J8999	Medical Oncology - CHEMO	ORAL	Primary		Y	
Degarelix	Firmagon	J9155	Medical Oncology - CHEMO	INJECTABLE	Primary		Y	
Denosumab	Xgeva, Prolia	J0897	Medical Oncology - SPORT	INJECTABLE	Supportive	◆ Excluding Xgeva	Y	
Denosumab	Xgeva, Prolia	J0897	Medical Oncology - CHEMO	INJECTABLE	Primary	◆ Excluding Xgeva	Y	Primary chemo pathway for the use of Xgeva to treat Giant Cell Tumor.

Effective Date: 01/01/24

Description	Alt Descriptions	HCPCS Code	Program	Administration Technique	Drug Class	Dual Indication symbol - 1199	1199 SEIU National Benefit Fund	Drug Comments
Dinutuximab	Unituxin	J1246	Medical Oncology - CHEMO	INJECTABLE	Primary		Y	New permanent HCPC Code: J1246 replacing NOC Codes: C9399 & J9999 for Unituxin, effective: 01/01/24
Dinutuximab	Unituxin	C9399	Medical Oncology - CHEMO	INJECTABLE	Primary		Y	NOC Code: C9399 will be replaced by new permanent HCPC Code J1246 for Unituxin, effective: 01/01/24
Dinutuximab	Unituxin	J9999	Medical Oncology - CHEMO	INJECTABLE	Primary		Y	NOC Code: J9999 will be replaced by new permanent HCPC Code J1246 for Unituxin, effective: 01/01/24
Docetaxel	Taxotere	J9171	Medical Oncology - CHEMO	INJECTABLE	Primary		Y	
Docetaxel (ingenus)		J9172	Medical Oncology - CHEMO	INJECTABLE	Primary		Y	New manufacture HCPC Code: J9172, for Doxetaxel, effective: 01/01/24
Dolasetron Mesylate	Anzemet	J8597	Medical Oncology - SPORT	ORAL	Supportive - Antiemetic		Y	
Dostarlimab-gxly	Jemperli	J9272	Medical Oncology - CHEMO	INJECTABLE	Primary		Y	
Doxorubicin HCL	Adriamycin	J9000	Medical Oncology - CHEMO	INJECTABLE	Primary		Y	
Doxorubicin HCL (liposomal)	Doxil, Doxorubicin HCL (Liposomal) not otherwise specified	Q2050	Medical Oncology - CHEMO	INJECTABLE	Primary		Y	
Durvalumab	Imfinzi	J9173	Medical Oncology - CHEMO	INJECTABLE	Primary		Y	
Duvelisib - oral	Copiktra	J8999	Medical Oncology - CHEMO	ORAL	Primary		Y	
Efbemalenograstim alfa-vuxw	Ryzneuta	C9399	Medical Oncology - SPORT	INJECTABLE	Supportive		Y	New supportive chemotherapy drug effective: 12/06/23
Efbemalenograstim alfa-vuxw	Ryzneuta	J3490	Medical Oncology - SPORT	INJECTABLE	Supportive		Y	New supportive chemotherapy drug effective: 12/06/23
Efbemalenograstim alfa-vuxw	Ryzneuta	J3590	Medical Oncology - SPORT	INJECTABLE	Supportive		Y	New supportive chemotherapy drug effective: 12/06/23
Efbemalenograstim alfa-vuxw	Ryzneuta	J9999	Medical Oncology - SPORT	INJECTABLE	Supportive		Y	New supportive chemotherapy drug effective: 12/06/23
Eflapegrastim-xnst	Rolvedon	J1449	Medical Oncology - SPORT	INJECTABLE	Supportive		Y	
Elacestrant - oral	Orserdu	J8999	Medical Oncology - CHEMO	ORAL	Primary		Y	
Elotuzumab	Empliciti	J9176	Medical Oncology - CHEMO	INJECTABLE	Primary		Y	
Elranatamab-bcmm	Elrexio	C9165	Medical Oncology - CHEMO	INJECTABLE	Primary		Y	New NOC Code: C9165 will replace NOC Code: C9399, effective: 01/01/24
Elranatamab-bcmm	Elrexio	C9399	Medical Oncology - CHEMO	INJECTABLE	Primary		Y	NOC Code: C9399 will be replaced by: C9165, effective: 01/01/24
Elranatamab-bcmm	Elrexio	J9999	Medical Oncology - CHEMO	INJECTABLE	Primary		Y	New primary chemotherapy drug effective: 09/01/23
Enasidenib - oral	IDHIFA	J8999	Medical Oncology - CHEMO	ORAL	Primary		Y	

Effective Date: 01/01/24

Description	Alt Descriptions	HCPCS Code	Program	Administration Technique	Drug Class	Dual Indication symbol - 1199	1199 SEIU National Benefit Fund	Drug Comments
Encorafenib - oral	Braftovi	J8999	Medical Oncology - CHEMO	ORAL	Primary		Y	
Enfortumab vedotin-efv	Padcev	J9177	Medical Oncology - CHEMO	INJECTABLE	Primary		Y	
Entrectinib - oral	Rozlytrek	J8999	Medical Oncology - CHEMO	ORAL	Primary		Y	
Enzalutamide - oral	Xtandi	J8999	Medical Oncology - CHEMO	ORAL	Primary		Y	
Epcoritamab-bysp	Epkinly	J9321	Medical Oncology - CHEMO	INJECTABLE	Primary		Y	New permanent HCPC Code: J9321 replacing NOC Codes: C9155 & J9999 for epcoritamab-bysp, effective: 01/01/24
Epcoritamab-bysp	Epkinly	C9155	Medical Oncology - CHEMO	INJECTABLE	Primary		Y	NOC Code: C9155 will be replaced by: J9321, effective: 01/01/24
Epcoritamab-bysp	Epkinly	J9999	Medical Oncology - CHEMO	INJECTABLE	Primary		Y	NOC Code: J9999 will be replaced by: J9321, effective: 01/01/24
Epirubicin	Ellence	J9178	Medical Oncology - CHEMO	INJECTABLE	Primary		Y	
Epoetin alfa	Epogen, Procrit	J0885	Medical Oncology - SPORT	INJECTABLE	Supportive	◆	Y	
Epoetin alfa-epbx	Retacrit	Q5106	Medical Oncology - SPORT	INJECTABLE	Supportive	◆	Y	
Erdafitinib-oral	Balversa	J8999	Medical Oncology - CHEMO	ORAL	Primary		Y	
Eribulin mesylate	Halaven	J9179	Medical Oncology - CHEMO	INJECTABLE	Primary		Y	
Erlotinib - oral	Tarceva	J8999	Medical Oncology - CHEMO	ORAL	Primary		Y	
Estramustine - oral	Emcyt	J8999	Medical Oncology - CHEMO	ORAL	Primary		Y	
Etoposide - inj	Toposar, VePesid, Etopophos	J9181	Medical Oncology - CHEMO	INJECTABLE	Primary		Y	
Etoposide - oral	Toposar	J8560	Medical Oncology - CHEMO	ORAL	Primary		Y	
Everolimus - oral	Afinitor	J8999	Medical Oncology - CHEMO	ORAL	Primary	◆	Y	
Fam-trastuzumab deruxtecan-nxki	Enhertu	J9358	Medical Oncology - CHEMO	INJECTABLE	Primary		Y	
Fedratinib - oral	Inrebic	J8999	Medical Oncology - CHEMO	ORAL	Primary		Y	
Filgrastim	Neupogen	J1442	Medical Oncology - SPORT	INJECTABLE	Supportive	◆	Y	
Filgrastim-aafi	Nivestym	Q5110	Medical Oncology - SPORT	INJECTABLE	Supportive	◆	Y	
Filgrastim-ayow	Releuko	Q5125	Medical Oncology - SPORT	INJECTABLE	Supportive	◆	Y	
Filgrastim-sndz	Zarxio	Q5101	Medical Oncology - SPORT	INJECTABLE	Supportive	◆	Y	
Floxuridine	FUDR	J9200	Medical Oncology - CHEMO	INJECTABLE	Primary		Y	
Fludarabine Phosphate	Fludara, Oforta	J9185	Medical Oncology - CHEMO	INJECTABLE	Primary		Y	
Fluoxymesterone - oral	Androxy	J8499	Medical Oncology - CHEMO	ORAL	Primary		Y	
Fosaprepitant	Emend	J1453	Medical Oncology - SPORT	INJECTABLE	Supportive - Antiemetic		Y	
Fosaprepitant (teva)		J1456	Medical Oncology - SPORT	INJECTABLE	Supportive - Antiemetic		Y	
Fosnetupitant/Palonosetron	Akynzeo	J1454	Medical Oncology - SPORT	INJECTABLE	Supportive - Antiemetic		Y	

Effective Date: 01/01/24

Description	Alt Descriptions	HCPCS Code	Program	Administration Technique	Drug Class	Dual Indication symbol - 1199	1199 SEIU National Benefit Fund	Drug Comments
Fruquintinib - oral	Fruzaqla	J8999	Medical Oncology - CHEMO	ORAL	Primary		Y	New primary oral chemotherapy effective: 12/06/23
Fulvestrant	Faslodex	J9395	Medical Oncology - CHEMO	INJECTABLE	Primary		Y	
Fulvestrant (Fresenius Kabi)		J9394	Medical Oncology - CHEMO	INJECTABLE	Primary		Y	
Fulvestrant (Teva)		J9393	Medical Oncology - CHEMO	INJECTABLE	Primary		Y	
Futibatinib - oral	Lytgobi	J8999	Medical Oncology - CHEMO	ORAL	Primary		Y	
Gefitinib - oral	Iressa	J8565	Medical Oncology - CHEMO	ORAL	Primary		Y	
Gemcitabine	Gemzar	J9201	Medical Oncology - CHEMO	INJECTABLE	Primary		Y	
Gemcitabine HCL in NaCL	Infugem	J9198	Medical Oncology - CHEMO	INJECTABLE	Primary		Y	
Gemcitabine Hydrochloride (accord)		J9196	Medical Oncology - CHEMO	INJECTABLE	Primary		Y	
Gemtuzumab Ozogamicin	Mylotarg	J9203	Medical Oncology - CHEMO	INJECTABLE	Primary		Y	
Gilteritinib - oral	Xospata	J8999	Medical Oncology - CHEMO	ORAL	Primary		Y	
Glasdegib - oral	Daurismo	J8999	Medical Oncology - CHEMO	ORAL	Primary		Y	
Glofitamab-gxbm	Columvi	J9286	Medical Oncology - CHEMO	INJECTABLE	Primary		Y	New permanent HCPC Code: J9286 replacing NOC Codes: C9399 & J9999, effective: 01/01/24
Glofitamab-gxbm	Columvi	C9399	Medical Oncology - CHEMO	INJECTABLE	Primary		Y	NOC Code: C9399 will be replaced by new permanent HCPC Code: J9286 for Columvi, effective: 01/01/24
Glofitamab-gxbm	Columvi	J9999	Medical Oncology - CHEMO	INJECTABLE	Primary		Y	NOC Code: J9999 will be replaced by new permanent HCPC Code: J9286 for Columvi, effective: 01/01/24
Goserelin acetate implant	Zoladex	J9202	Medical Oncology - CHEMO	INJECTABLE	Primary	◆	Y	
Granisetron - subcutaneous	Sustol	J1627	Medical Oncology - SPORT	INJECTABLE	Supportive - Antiemetic		Y	
Histrelin Implant	Vantas	J9225	Medical Oncology - CHEMO	INJECTABLE	Primary		Y	
Ibrutinib - oral	Imbruvica	J8999	Medical Oncology - CHEMO	ORAL	Primary	◆	Y	
Idarubicin HCL - inj	Idamycin	J9211	Medical Oncology - CHEMO	INJECTABLE	Primary		Y	
Idelalisib - oral	Zydelig	J8999	Medical Oncology - CHEMO	ORAL	Primary		Y	
Ifosfamide	Ifex, Mitoxana	J9208	Medical Oncology - CHEMO	INJECTABLE	Primary		Y	
Imatinib - oral	Gleevec	J8999	Medical Oncology - CHEMO	ORAL	Primary		Y	
Imatinib - oral	Gleevec	S0088	Medical Oncology - CHEMO	ORAL	Primary		Y	
Inotuzumab Ozogamicin	Besponsa	J9229	Medical Oncology - CHEMO	INJECTABLE	Primary		Y	
Interferon, alfa-2b, recombinant	Intron A	J9214	Medical Oncology - CHEMO	INJECTABLE	Primary		Y	
Interferon, gamma-1b	Actimmune	J9216	Medical Oncology - CHEMO	INJECTABLE	Primary		Y	

Effective Date: 01/01/24

Description	Alt Descriptions	HCPCS Code	Program	Administration Technique	Drug Class	Dual Indication symbol - 1199	1199 SEIU National Benefit Fund	Drug Comments
Ipilimumab	Yervoy	J9228	Medical Oncology - CHEMO	INJECTABLE	Primary		Y	
Irinotecan	Camptosar	J9206	Medical Oncology - CHEMO	INJECTABLE	Primary		Y	
Irinotecan Liposome	Onivyde	J9205	Medical Oncology - CHEMO	INJECTABLE	Primary		Y	
Isatuximab-irfc	Sarclisa	J9227	Medical Oncology - CHEMO	INJECTABLE	Primary		Y	
Ivosidenib - oral	Tibsovo	J8999	Medical Oncology - CHEMO	ORAL	Primary		Y	
Ixabepilone	Ixempra	J9207	Medical Oncology - CHEMO	INJECTABLE	Primary		Y	
Ixazomib - oral	Ninlaro	J8999	Medical Oncology - CHEMO	ORAL	Primary		Y	
Lanreotide	Somatuline Depot	J1930	Medical Oncology - CHEMO	INJECTABLE	Primary	◆	Y	
Lanreotide (Cipla)		J1932	Medical Oncology - CHEMO	INJECTABLE	Primary	◆	Y	
Lapatinib - oral	Tykerb	J8999	Medical Oncology - CHEMO	ORAL	Primary		Y	
Larotrectinib - oral	Vittrakvi	J8999	Medical Oncology - CHEMO	ORAL	Primary		Y	
Lenalidomide - oral	Revlimid	J8999	Medical Oncology - CHEMO	ORAL	Primary		Y	
Lenvatinib - oral	Lenvima	J8999	Medical Oncology - CHEMO	ORAL	Primary		Y	
Leucovorin - inj		J0640	Medical Oncology - CHEMO	INJECTABLE	Primary		Y	
Leucovorin - oral	Leucovorin	J8999	Medical Oncology - CHEMO	ORAL	Primary		Y	
Leuprolide Acetate		J1954	Medical Oncology - CHEMO	INJECTABLE	Primary		Y	
Leuprolide Acetate (J1950: 3.75mg)	Eligard, Lupron Depot, Lupron, Leuprolide Acetate	J1950	Medical Oncology - CHEMO	INJECTABLE	Primary	◆ Excluding Eligard	Y	
Leuprolide Acetate (J9217: 7.5mg)	Eligard, Lupron Depot, Lupron, Leuprolide Acetate	J9217	Medical Oncology - CHEMO	INJECTABLE	Primary	◆ Excluding Eligard	Y	
Leuprolide Acetate (J9218: 1mg)	Lupron	J9218	Medical Oncology - CHEMO	INJECTABLE	Primary	◆ Excluding Eligard	Y	
Leuprolide Mesylate	Camcevi	J1952	Medical Oncology - CHEMO	INJECTABLE	Primary		Y	
Levoleucovorin	Fusilev	J0641	Medical Oncology - CHEMO	INJECTABLE	Primary		Y	
Levoleucovorin	Khazpory	J0642	Medical Oncology - CHEMO	INJECTABLE	Primary		Y	
Liposome-encapsulated combination of Daunorubicin and Cytarabine	Vyxeos	J9153	Medical Oncology - CHEMO	INJECTABLE	Primary		Y	
Lomustine - oral	Gleostine, CCNU	S0178	Medical Oncology - CHEMO	ORAL	Primary		Y	
Loncastuximab tesirine-lpyl	Zynlonta	J9359	Medical Oncology - CHEMO	INJECTABLE	Primary		Y	
Lorlatinib - oral	Lorbrena	J8999	Medical Oncology - CHEMO	ORAL	Primary		Y	
Lurbinectedin	Zepzelca	J9223	Medical Oncology - CHEMO	INJECTABLE	Primary		Y	
Luspatercept-aamt	Reblozyl	J0896	Medical Oncology - SPORT	INJECTABLE	Supportive	◆	Y	
Margetuximab-cmkb	Margenza	J9353	Medical Oncology - CHEMO	INJECTABLE	Primary		Y	
Mechlorethamine - topical	Valchlor	J9999	Medical Oncology - CHEMO	TOPICAL	Primary		Y	
Melphalan HCL - inj	Evomela	J9246	Medical Oncology - CHEMO	INJECTABLE	Primary		Y	

Effective Date: 01/01/24

Description	Alt Descriptions	HCPCS Code	Program	Administration Technique	Drug Class	Dual Indication symbol - 1199	1199 SEIU National Benefit Fund	Drug Comments
Melphalan HCL - NOS inj	Alkeran	J9245	Medical Oncology - CHEMO	INJECTABLE	Primary		Y	
Mesna	Mesnex	J9209	Medical Oncology - SPORT	INJECTABLE	Supportive		Y	
Methotrexate (accord)		J9255	Medical Oncology - CHEMO	INJECTABLE	Primary	◆	Y	New manufacture HCPC Code: J9255 for Methotrexate, effective: 01/01/24
Methotrexate Sodium (J9250: 5mg)	Folex, Methotrexate	J9250	Medical Oncology - CHEMO	INJECTABLE	Primary	◆	Y	
Methotrexate Sodium (J9260: 50mg)	Folex, Methotrexate	J9260	Medical Oncology - CHEMO	INJECTABLE	Primary		Y	
Midostaurin - oral	Rydapt	J8999	Medical Oncology - CHEMO	ORAL	Primary		Y	
Mirvetuximab Soravtansine-gynx	Elahere	J9063	Medical Oncology - CHEMO	INJECTABLE	Primary		Y	
Mitomycin	Jelmyto	J9281	Medical Oncology - CHEMO	PYELOCALYCEAL	Primary		Y	
Mitomycin	Mutamycin	J9280	Medical Oncology - CHEMO	INJECTABLE	Primary		Y	
Mitotane - oral	Lysodren	J8999	Medical Oncology - CHEMO	ORAL	Primary		Y	
Mitoxantrone HCL	Novantrone	J9293	Medical Oncology - CHEMO	INJECTABLE	Primary		Y	
Mobocertinib - oral	Exkivity	J8999	Medical Oncology - CHEMO	ORAL	Primary		Y	
Mogamulizumab-kpkc	Poteligeo	J9204	Medical Oncology - CHEMO	INJECTABLE	Primary		Y	
Momelotinib	Oijaara	C9399	Medical Oncology - CHEMO	ORAL	Primary		Y	New oral primary chemotherapy drug; Effective: 10/05/23
Momelotinib	Oijaara	J3490	Medical Oncology - CHEMO	ORAL	Primary		Y	New oral primary chemotherapy drug; Effective: 10/05/23
Momelotinib	Oijaara	J3590	Medical Oncology - CHEMO	ORAL	Primary		Y	New oral primary chemotherapy drug; Effective: 10/05/23
Momelotinib	Oijaara	J9999	Medical Oncology - CHEMO	ORAL	Primary		Y	New oral primary chemotherapy drug; Effective: 10/05/23
Mosunetuzumab-axgb	Lunsumio	J9350	Medical Oncology - CHEMO	INJECTABLE	Primary		Y	
Moxetumomab pasudotox-tdfk	Lumoxiti	J9313	Medical Oncology - CHEMO	INJECTABLE	Primary		Y	
Nadofaragen Firadenovec-vncg	Adstiladrin	J9029	Medical Oncology - CHEMO	INJECTABLE	Primary		Y	
Naxitamab-ggqk	Danyelza	J9348	Medical Oncology - CHEMO	INJECTABLE	Primary		Y	
Necitumumab	Portrazza	J9295	Medical Oncology - CHEMO	INJECTABLE	Primary		Y	
Nelarabine	Arranon	J9261	Medical Oncology - CHEMO	INJECTABLE	Primary		Y	
Neratinib - oral	Nerlynx	J8999	Medical Oncology - CHEMO	ORAL	Primary		Y	
Netupitant/Palonosetron - oral	Akynzeo	J8655	Medical Oncology - SPORT	ORAL	Supportive - Antiemetic		Y	
Nilotinib - oral	Tasigna	J8999	Medical Oncology - CHEMO	ORAL	Primary		Y	
Niraparib - oral	Zejula	J8999	Medical Oncology - CHEMO	ORAL	Primary		Y	
Niraparib and Abiraterone Acetate - Oral	Akeega	J8999	Medical Oncology - CHEMO	ORAL	Primary		Y	

Effective Date: 01/01/24

Description	Alt Descriptions	HCPCS Code	Program	Administration Technique	Drug Class	Dual Indication symbol - 1199	1199 SEIU National Benefit Fund	Drug Comments
Nirogacestat - oral	Ogsiveo	J8999	Medical Oncology - CHEMO	ORAL	Primary		Y	New primary oral chemotherapy effective: 12/06/23
Nivolumab	Opdivo	J9299	Medical Oncology - CHEMO	INJECTABLE	Primary		Y	
Nivolumab and Relatlimab-rmbw	Opdualag	J9298	Medical Oncology - CHEMO	INJECTABLE	Primary		Y	
Obinutuzumab	Gazyva	J9301	Medical Oncology - CHEMO	INJECTABLE	Primary		Y	
Octreotide depot	Sandostatin	J2353	Medical Oncology - CHEMO	INJECTABLE	Primary	◆	Y	
Octreotide depot	Sandostatin	J2353	Medical Oncology - SPORT	INJECTABLE	Supportive	◆	Y	
Octreotide non-depot	Sandostatin	J2354	Medical Oncology - CHEMO	INJECTABLE	Primary	◆	Y	
Octreotide non-depot	Sandostatin	J2354	Medical Oncology - SPORT	INJECTABLE	Supportive	◆	Y	
Ofatumumab	Arzerra	J9302	Medical Oncology - CHEMO	INJECTABLE	Primary		Y	
Olaparib - oral	Lynparza	J8999	Medical Oncology - CHEMO	ORAL	Primary		Y	
Olutasidenib - oral	Rezlidhia	J8999	Medical Oncology - CHEMO	ORAL	Primary		Y	
Omacetaxine	Synribo	J9262	Medical Oncology - CHEMO	INJECTABLE	Primary		Y	
Osimertinib - oral	Tagrisso	J8999	Medical Oncology - CHEMO	ORAL	Primary		Y	
Oxaliplatin	Eloxatin	J9263	Medical Oncology - CHEMO	INJECTABLE	Primary		Y	
Paclitaxel	Nov-Onxol, Taxol	J9267	Medical Oncology - CHEMO	INJECTABLE	Primary		Y	
Paclitaxel (albumin-bound)	Abraxane	J9264	Medical Oncology - CHEMO	INJECTABLE	Primary		Y	
Paclitaxel albumin-bound (American Regent)		J9259	Medical Oncology - CHEMO	INJECTABLE	Primary		Y	
Paclitaxel protein-bound (teva)		J9258	Medical Oncology - CHEMO	INJECTABLE	Primary		Y	New manufacture HCPC Code: J9258 for Paclitaxel, effective: 01/01/24
Pacritinib - oral	Vonjo	J8999	Medical Oncology - CHEMO	ORAL	Primary		Y	
Palbociclib - oral	Ibrance	J8999	Medical Oncology - CHEMO	ORAL	Primary		Y	
Palonosetron	Aloxi	J2469	Medical Oncology - SPORT	INJECTABLE	Supportive - Antiemetic		Y	
Pamidronate Disodium	Aredia	J2430	Medical Oncology - SPORT	INJECTABLE	Supportive		Y	
Panitumumab	Vectibix	J9303	Medical Oncology - CHEMO	INJECTABLE	Primary		Y	
Pazopanib - oral	Votrient	J8999	Medical Oncology - CHEMO	ORAL	Primary		Y	
Pegaspargase	Oncaspar	J9266	Medical Oncology - CHEMO	INJECTABLE	Primary		Y	
Pegfilgrastim, excludes biosimilar, 0.5 mg	Neulasta	J2506	Medical Oncology - SPORT	INJECTABLE	Supportive		Y	
Pegfilgrastim-apgf	Nyvepria	Q5122	Medical Oncology - SPORT	INJECTABLE	Supportive		Y	
Pegfilgrastim-bmez	Ziextenzo	Q5120	Medical Oncology - SPORT	INJECTABLE	Supportive		Y	
Pegfilgrastim-cbqv	Udenyca	Q5111	Medical Oncology - SPORT	INJECTABLE	Supportive		Y	
Pegfilgrastim-fpgk	Stimufend	Q5127	Medical Oncology - SPORT	INJECTABLE	Supportive		Y	

Effective Date: 01/01/24

Description	Alt Descriptions	HCPCS Code	Program	Administration Technique	Drug Class	Dual Indication symbol - 1199	1199 SEIU National Benefit Fund	Drug Comments
Pegfilgrastim-jmdb	Fulphila	Q5108	Medical Oncology - SPORT	INJECTABLE	Supportive		Y	
Pegfilgrastim-pbbk	Fylnetra	Q5130	Medical Oncology - SPORT	INJECTABLE	Supportive		Y	
Peginterferon, alfa-2a	Pegasys	J3590	Medical Oncology - CHEMO	INJECTABLE	Primary	◆	Y	
Peginterferon, alfa-2a	Pegasys	S0145	Medical Oncology - CHEMO	INJECTABLE	Primary	◆	Y	
Peginterferon, alfa-2b	PegIntron	J3590	Medical Oncology - CHEMO	INJECTABLE	Primary	◆	Y	
Peginterferon, alfa-2b	PegIntron	S0148	Medical Oncology - CHEMO	INJECTABLE	Primary	◆	Y	
Pembrolizumab	Keytruda	J9271	Medical Oncology - CHEMO	INJECTABLE	Primary		Y	
Pemetrexed	Alimta, Pemetrexed not otherwise specified	J9305	Medical Oncology - CHEMO	INJECTABLE	Primary		Y	
Pemetrexed	Pemfexy	J9304	Medical Oncology - CHEMO	INJECTABLE	Primary		Y	
Pemetrexed (accord)		J9296	Medical Oncology - CHEMO	INJECTABLE	Primary		Y	
Pemetrexed (bluepoint)		J9322	Medical Oncology - CHEMO	INJECTABLE	Primary		Y	
Pemetrexed (hospira)		J9294	Medical Oncology - CHEMO	INJECTABLE	Primary		Y	
Pemetrexed (hospira)		J9323	Medical Oncology - CHEMO	INJECTABLE	Primary		Y	
Pemetrexed (pemrydi rtu)		J9324	Medical Oncology - CHEMO	INJECTABLE	Primary		Y	New manufacture HCPC Code: J9324 for Pemetrexed, effective: 01/01/24
Pemetrexed (sandoz)		J9297	Medical Oncology - CHEMO	INJECTABLE	Primary		Y	
Pemetrexed (Teva)		J9314	Medical Oncology - CHEMO	INJECTABLE	Primary		Y	
Pemigatinib - oral	Pemazyre	J8999	Medical Oncology - CHEMO	ORAL	Primary		Y	
Pentostatin	Nipent	J9268	Medical Oncology - CHEMO	INJECTABLE	Primary		Y	
Pertuzumab	Perjeta	J9306	Medical Oncology - CHEMO	INJECTABLE	Primary		Y	
Pertuzumab / trastuzumab / hyaluronidase-zzxf	Phesgo	J9316	Medical Oncology - CHEMO	INJECTABLE	Primary		Y	
Pexidartinib - oral	Turalio	J8999	Medical Oncology - CHEMO	ORAL	Primary		Y	
Pirtobrutinib - oral	Jaypirca	J8999	Medical Oncology - CHEMO	ORAL	Primary		Y	
Polatuzumab vedotin-piiq	Polivy	J9309	Medical Oncology - CHEMO	INJECTABLE	Primary		Y	
Pomalidomide - oral	Pomalyst	J8999	Medical Oncology - CHEMO	ORAL	Primary		Y	
Ponatinib - oral	Iclusig	J8999	Medical Oncology - CHEMO	ORAL	Primary		Y	
Porfimer Sodium	Photofrin	J9600	Medical Oncology - CHEMO	INJECTABLE	Primary		Y	
Pralatrexate	Folotyn	J9307	Medical Oncology - CHEMO	INJECTABLE	Primary		Y	
Pralsetinib - oral	Gavreto	J8999	Medical Oncology - CHEMO	ORAL	Primary		Y	
Procarbazine - oral	Matulane	J8999	Medical Oncology - CHEMO	ORAL	Primary		Y	
Procarbazine - oral	Matulane	S0182	Medical Oncology - CHEMO	ORAL	Primary		Y	
Quizartinib - oral	Vanflyta	J8999	Medical Oncology - CHEMO	ORAL	Primary		Y	

Effective Date: 01/01/24

Description	Alt Descriptions	HCPCS Code	Program	Administration Technique	Drug Class	Dual Indication symbol - 1199	1199 SEIU National Benefit Fund	Drug Comments
Ramucirumab	Cyramza	J9308	Medical Oncology - CHEMO	INJECTABLE	Primary		Y	
Regorafenib - oral	Stivarga	J8999	Medical Oncology - CHEMO	ORAL	Primary		Y	
Relugolix - oral	Orgovyx	J8999	Medical Oncology - CHEMO	ORAL	Primary		Y	
Reprotectinib - oral	Augtyro	J8999	Medical Oncology - CHEMO	ORAL	Primary		Y	New primary oral chemotherapy effective: 12/06/23
Retifanlimab-dlwr	Zynyz	J9345	Medical Oncology - CHEMO	INJECTABLE	Primary		Y	
Ribociclib - oral	Kisqali	J8999	Medical Oncology - CHEMO	ORAL	Primary		Y	
Ripretinib - oral	Qinlock	J8999	Medical Oncology - CHEMO	ORAL	Primary		Y	
Rituximab	Rituxan	J9312	Medical Oncology - CHEMO	INJECTABLE	Primary	◆	Y	
Rituximab and Hyaluronidase Human	Rituxan Hycela	J9311	Medical Oncology - CHEMO	INJECTABLE	Primary		Y	
Rituximab-abbs	Truxima	Q5115	Medical Oncology - CHEMO	INJECTABLE	Primary - Biosimilar	◆	Y	
Rituximab-arxx	Riabni	Q5123	Medical Oncology - CHEMO	INJECTABLE	Primary - Biosimilar	◆	Y	
Rituximab-pvvr	Ruxience	Q5119	Medical Oncology - CHEMO	INJECTABLE	Primary - Biosimilar	◆	Y	
Rolapitant - oral	Varubi	J8670	Medical Oncology - SPORT	ORAL	Supportive - Antiemetic		Y	
Romidepsin (lyophilized)	Istodax	J9319	Medical Oncology - CHEMO	INJECTABLE	Primary		Y	
Romidepsin (non-lyophilized)		J9318	Medical Oncology - CHEMO	INJECTABLE	Primary		Y	
Ropeginterferon alfa-2b-njft	Besremi	C9399	Medical Oncology - CHEMO	INJECTABLE	Primary		Y	
Ropeginterferon alfa-2b-njft	Besremi	J9999	Medical Oncology - CHEMO	INJECTABLE	Primary		Y	
Rucaparib - oral	Rubraca	J8999	Medical Oncology - CHEMO	ORAL	Primary		Y	
Ruxolitinib - oral	Jakafi	J8999	Medical Oncology - CHEMO	ORAL	Primary	◆	Y	
Sacituzumab govitecan-hziy	Trodelyv	J9317	Medical Oncology - CHEMO	INJECTABLE	Primary		Y	
Sargramostim	Leukine	J2820	Medical Oncology - SPORT	INJECTABLE	Supportive		Y	
Selinexor - oral	Xpovio	J8999	Medical Oncology - CHEMO	ORAL	Primary		Y	
Selpercatinib - oral	Retevmo	J8999	Medical Oncology - CHEMO	ORAL	Primary		Y	
Selumetinib - oral	Koselugo	J8999	Medical Oncology - CHEMO	ORAL	Primary	◆	Y	
Siltuximab	Sylvant	J2860	Medical Oncology - CHEMO	INJECTABLE	Primary		Y	
Sipuleucel-T	Provenge	Q2043	Medical Oncology - CHEMO	INJECTABLE	Primary		Y	
Sirolimus protein-bound particles for injectable suspension (albumin bound)	Fyarro	J9331	Medical Oncology - CHEMO	INJECTABLE	Primary		Y	
Sodium Thiosulfate Injection	Pedmark	J0208	Medical Oncology - SPORT	INJECTABLE	Supportive		Y	
Sonidegib - oral	Odomzo	J8999	Medical Oncology - CHEMO	ORAL	Primary		Y	
Sorafenib Tosylate - oral	Nexavar	J8999	Medical Oncology - CHEMO	ORAL	Primary		Y	
Sotorasib - oral	Lumakras	J8999	Medical Oncology - CHEMO	ORAL	Primary		Y	

Effective Date: 01/01/24

Description	Alt Descriptions	HCPCS Code	Program	Administration Technique	Drug Class	Dual Indication symbol - 1199	1199 SEIU National Benefit Fund	Drug Comments
Streptozocin	Zanosar	J9320	Medical Oncology - CHEMO	INJECTABLE	Primary		Y	
Sunitinib - oral	Sutent	J8999	Medical Oncology - CHEMO	ORAL	Primary		Y	
Tafasitamab-cxix	Monjuvi	J9349	Medical Oncology - CHEMO	INJECTABLE	Primary		Y	
Tagraxofusp-erzs	Elzonris	J9269	Medical Oncology - CHEMO	INJECTABLE	Primary		Y	
Talazoparib - oral	Talzenna	J8999	Medical Oncology - CHEMO	ORAL	Primary		Y	
Talimogene Laherparepvec	Imlygic	J9325	Medical Oncology - CHEMO	INJECTABLE	Primary		Y	
Talquetamab-tgvs	Talvey	C9163	Medical Oncology - CHEMO	INJECTABLE	Primary		Y	NOC Code C9163 will replace NOC Code: C9399, effective: 01/01/24
Talquetamab-tgvs	Talvey	C9399	Medical Oncology - CHEMO	INJECTABLE	Primary		Y	NOC Code C9399 will be replaced by NOC Code: C9163, effective: 01/01/24
Talquetamab-tgvs	Talvey	J9999	Medical Oncology - CHEMO	INJECTABLE	Primary		Y	New primary chemotherapy drug effective: 09/01/23
Tazemetostat - oral	Tazverik	J8999	Medical Oncology - CHEMO	ORAL	Primary		Y	
Tbo-filgrastim	Granix	J1447	Medical Oncology - SPORT	INJECTABLE	Supportive		Y	
Tebentafusp-tebn	Kimmtrak	J9274	Medical Oncology - CHEMO	INJECTABLE	Primary		Y	
Teclistamab-cqyv	Tecvayli	J9380	Medical Oncology - CHEMO	INJECTABLE	Primary		Y	
Telotristat ethyl - oral	Xermelo	J8499	Medical Oncology - SPORT	ORAL	Supportive		Y	
Temozolomide - inj	Temodar	J9328	Medical Oncology - CHEMO	INJECTABLE	Primary		Y	
Temozolomide - oral	Temodar	J8700	Medical Oncology - CHEMO	ORAL	Primary		Y	
Temsrolimus	Torisel	J9330	Medical Oncology - CHEMO	INJECTABLE	Primary		Y	
Teniposide	Vumon	Q2017	Medical Oncology - CHEMO	INJECTABLE	Primary		Y	
Tepotinib - oral	Tepmetko	J8999	Medical Oncology - CHEMO	ORAL	Primary		Y	
Thalidomide - oral	Thalomid	J8999	Medical Oncology - CHEMO	ORAL	Primary	◆	Y	
Thiotepa	Thiotepex	J9340	Medical Oncology - CHEMO	INJECTABLE	Primary		Y	
Tisotumab vedotin-tftv	Tivdak	J9273	Medical Oncology - CHEMO	INJECTABLE	Primary		Y	
Tivozanib - oral	Fotivda	J8999	Medical Oncology - CHEMO	ORAL	Primary		Y	
Tocilizumab	Actemra	J3262	Medical Oncology - SPORT	INJECTABLE	Supportive	◆	Y	Supportive pathway for the use of Actemra for CAR-T induced CRS
Tocilizumab	Actemra	J3262	Medical Oncology - CHEMO	INJECTABLE	Primary	◆	Y	
Tocilizumab-bavi	Tofidence	C9399	Medical Oncology - CHEMO	INJECTABLE	Primary - Biosimilar		Y	New primary biosimilar for Tocilizumab-bavi effective: 11/16/23
Tocilizumab-bavi	Tofidence	J3490	Medical Oncology - CHEMO	INJECTABLE	Primary - Biosimilar		Y	New primary biosimilar for Tocilizumab-bavi effective: 11/16/23

Effective Date: 01/01/24

Description	Alt Descriptions	HCPCS Code	Program	Administration Technique	Drug Class	Dual Indication symbol - 1199	1199 SEIU National Benefit Fund	Drug Comments
Tocilizumab-bavi	Tofidence	J3590	Medical Oncology - CHEMO	INJECTABLE	Primary - Biosimilar		Y	New primary biosimilar for Tocilizumab-bavi effective: 11/16/23
Tocilizumab-bavi	Tofidence	J9999	Medical Oncology - CHEMO	INJECTABLE	Primary - Biosimilar		Y	New primary biosimilar for Tocilizumab-bavi effective: 11/16/23
Tocilizumab-bavi	Tofidence	C9399	Medical Oncology - SPORT	INJECTABLE	Supportive		Y	New supportive biosimilar for Tocilizumab-bavi, for the use of Actemra for CAR-T induced CRS effective: 11/16/23
Tocilizumab-bavi	Tofidence	J3490	Medical Oncology - SPORT	INJECTABLE	Supportive		Y	New supportive biosimilar for Tocilizumab-bavi, for the use of Actemra for CAR-T induced CRS effective: 11/16/23
Tocilizumab-bavi	Tofidence	J3590	Medical Oncology - SPORT	INJECTABLE	Supportive		Y	New supportive biosimilar for Tocilizumab-bavi, for the use of Actemra for CAR-T induced CRS effective: 11/16/23
Tocilizumab-bavi	Tofidence	J9999	Medical Oncology - SPORT	INJECTABLE	Supportive		Y	New supportive biosimilar for Tocilizumab-bavi, for the use of Actemra for CAR-T induced CRS effective: 11/16/23
Topotecan - inj	Hycamtin	J9351	Medical Oncology - CHEMO	INJECTABLE	Primary		Y	
Topotecan - oral	Hycamtin	J8705	Medical Oncology - CHEMO	ORAL	Primary		Y	
Toripalimab-tpzi	Loqtorz	C9399	Medical Oncology - CHEMO	INJECTABLE	Primary		Y	New primary chemotherapy drug effective: 11/03/23
Toripalimab-tpzi	Loqtorz	J3490	Medical Oncology - CHEMO	INJECTABLE	Primary		Y	New primary chemotherapy drug effective: 11/03/23
Toripalimab-tpzi	Loqtorz	J3590	Medical Oncology - CHEMO	INJECTABLE	Primary		Y	New primary chemotherapy drug effective: 11/03/23
Toripalimab-tpzi	Loqtorz	J9999	Medical Oncology - CHEMO	INJECTABLE	Primary		Y	New primary chemotherapy drug effective: 11/03/23
Trabectedin	Yondelis	J9352	Medical Oncology - CHEMO	INJECTABLE	Primary		Y	
Trametinib - oral	Mekinist	J8999	Medical Oncology - CHEMO	ORAL	Primary		Y	
Trametinib - powder for suspension	Mekinist	J8999	Medical Oncology - CHEMO	ORAL	Primary		Y	
Trastuzumab	Herceptin	J9355	Medical Oncology - CHEMO	INJECTABLE	Primary		Y	
Trastuzumab and hyaluronidase-oysk	Herceptin Hylecta	J9356	Medical Oncology - CHEMO	INJECTABLE	Primary		Y	
Trastuzumab-anns	Kanjinti	Q5117	Medical Oncology - CHEMO	INJECTABLE	Primary - Biosimilar		Y	
Trastuzumab-dkst	Ogivri	Q5114	Medical Oncology - CHEMO	INJECTABLE	Primary - Biosimilar		Y	
Trastuzumab-dttb	Ontruzant	Q5112	Medical Oncology - CHEMO	INJECTABLE	Primary - Biosimilar		Y	
Trastuzumab-pkrb	Herzuma	Q5113	Medical Oncology - CHEMO	INJECTABLE	Primary - Biosimilar		Y	

Effective Date: 01/01/24

Description	Alt Descriptions	HCPCS Code	Program	Administration Technique	Drug Class	Dual Indication symbol - 1199	1199 SEIU National Benefit Fund	Drug Comments
Trastuzumab-qyyp	Trazimera	Q5116	Medical Oncology - CHEMO	INJECTABLE	Primary - Biosimilar		Y	
Tremelimumab-aclt	Imjudo	J9347	Medical Oncology - CHEMO	INJECTABLE	Primary		Y	
Trifluridine/Tipiracil - oral	Lonsurf	J8999	Medical Oncology - CHEMO	ORAL	Primary		Y	
Trilaciclib	Cosela	J1448	Medical Oncology - SPORT	INJECTABLE	Supportive		Y	
Triptorelin Pamoate	Trelstar	J3315	Medical Oncology - CHEMO	INJECTABLE	Primary		Y	
Tucatinib - oral	Tukysa	J8999	Medical Oncology - CHEMO	ORAL	Primary		Y	
Umbraisib - oral	Ukoniq	J8999	Medical Oncology - CHEMO	ORAL	Primary		Y	
Valrubicin	Valstar	J9357	Medical Oncology - CHEMO	INJECTABLE	Primary		Y	
Vandetanib - oral	Caprelsa	J8999	Medical Oncology - CHEMO	ORAL	Primary		Y	
Vemurafenib - oral	Zelboraf	J8999	Medical Oncology - CHEMO	ORAL	Primary		Y	
Venetoclax - oral	Venclexta	J8999	Medical Oncology - CHEMO	ORAL	Primary		Y	
Vinblastine Sulfate	Velban	J9360	Medical Oncology - CHEMO	INJECTABLE	Primary		Y	
Vincristine Sulfate	Oncovin, Vincasar PFS	J9370	Medical Oncology - CHEMO	INJECTABLE	Primary		Y	
Vinorelbine Tartrate	Navelbine	J9390	Medical Oncology - CHEMO	INJECTABLE	Primary		Y	
Vismodegib - oral	Erivedge	J8999	Medical Oncology - CHEMO	ORAL	Primary		Y	
Vorinostat - oral	Zolinza	J8999	Medical Oncology - CHEMO	ORAL	Primary		Y	
Zanubrutinib - oral	Brukinsa	J8999	Medical Oncology - CHEMO	ORAL	Primary		Y	
Zivafibercept	Zaltrap	J9400	Medical Oncology - CHEMO	INJECTABLE	Primary		Y	
Zoledronic Acid	Zoledronic Acid	J3489	Medical Oncology - SPORT	INJECTABLE	Supportive	◆	Y	